2. Academic Validation
  3. PSMA-targeted low-molecular double conjugates for diagnostics and therapy

PSMA-targeted low-molecular double conjugates for diagnostics and therapy

  • Eur J Med Chem. 2021 Dec 5:225:113752. doi: 10.1016/j.ejmech.2021.113752.
Stanislav A Petrov 1,  Nikolay Y Zyk 1,  Aleksei E Machulkin 2,  Elena K Beloglazkina 1,  Alexander G Majouga 3
Affiliations

Affiliations

  • 1 Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
  • 2 Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia. Electronic address: [email protected].
  • 3 Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia; Laboratory of Biomedical Nanomaterials, National University of Science and Technology MISiS, Moscow, Russia; Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
PMID: 34464875 DOI: 10.1016/j.ejmech.2021.113752
Abstract

This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate Cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed.

Keywords

Anticancer drugs; Cancer diagnosis; Double conjugates; PSMA; Prostate cancer; Targeted delivery.

Figures